Doesn't that go to secured holders of debt ? What is left for commons shareholders and why do you longs think you will get anything. There is about 125 million shares outstanding ? If they have 700 million in debt that would be $5.60 a share to just pay off debt. Can we do the math without bashing ( yeah right ). If it has been done already excuse me. Let's do it again. Thanks
unless they complete the transaction. Meaning they HAVE to buy the shares and deliver or the value they have built uo in their accounts is just a number (credit ) but not accessible. They have to buy it to get their profit. That said the stock and company ultimately ( like Enron even not yet ) can been deemed worthless, but that takes years. The bottom line is the stock will have to be bought back by shorts and that in itself will create demand notwithstanding the financial condition of the company.
yes I sold at a loss back at $4. Can't win them all. Will try to recoup some of the losses now. We will see. Not saying you should or shouldn't. Just what I did. Good luck to all. Maybe we'll get some pennies back :)
Dendreon Releases Encouraging Long-Term Analysis of PROVENGE in Phase II STAND Study 04/11 11-Apr-14 07:13:00
07:13 AM EDT, 04/11/2014 (MT Newswires) -- Dendreon (DNDN:$2.78,00$-0.12,00-4.14%) released preliminary data Friday showing a long-term analysis of the biotechnology company's Phase II STAND study demonstrated that tumor-specific T-cell responses appear to be enhanced and sustained when its PROVENGE treatment is given after androgen deprivation therapy or ADT in patients with biochemically recurrent prostate cancer at high risk for metastases.
The STAND study is a randomized, Phase II trial that consisted of two patient study groups, one completing PROVENGE two weeks before ADT and the second receiving PROVENGE three months after the start of ADT. Preliminary results suggest enhanced cellular immune responses when PROVENGE was given after ADT, and these responses were persistent for at least 12 months and robust in both patient groups, the company said.
167 posts in 8 days. What new handles will you spring up from next. You post nonsense sir.
how long they've been dogging us !!!
sounds like fear to me. They are desperately trying to cover. They even short more to shake loose shares.
Domain Name: sipuleucel-t.com
Registry Domain ID: 1555250371_DOMAIN_COM-VRSN
Registrar WHOIS Server: whois.markmonitor.com
Registrar URL: http://www.markmonitor.com
Updated Date: 2013-12-03T12:35:01-0800
Creation Date: 2011-02-28T13:57:44-0800
Registrar Registration Expiration Date: 2014-05-10T17:29:52-0700
Registrar: MarkMonitor, Inc.
Registrar IANA ID: 292
Registrar Abuse Contact Email: Email Masking Image@markmonitor.com
Registrar Abuse Contact Phone: +1.2083895740
Domain Status: clientUpdateProhibited
Domain Status: clientTransferProhibited
Domain Status: clientDeleteProhibited
Registry Registrant ID:
Registrant Name: Domain Administrator
Registrant Organization: Allergan, Inc.
Registrant Street: 2525 Dupont Drive,
Registrant City: Irvine
Registrant State/Province: CA
Registrant Postal Code: 92612
Registrant Country: US
Registrant Phone: +1.7142466799
Registrant Phone Ext:
Registrant Fax: +1.7142462418
Registrant Fax Ext:
Registrant Email: Email Masking Image@allergan.com
Registry Admin ID:
Admin Name: Domain Administrator
Admin Organization: Allergan, Inc.
Admin Street: 2525 Dupont Drive,
Admin City: Irvine
Admin State/Province: CA
Admin Postal Code: 92612
Admin Country: US
Admin Phone: +1.7142466799
Admin Phone Ext:
Admin Fax: +1.7142462418
Admin Fax Ext:
Admin Email: Email Masking Image@allergan.com
Registry Tech ID:
Tech Name: Domain Administrator
Tech Organization: Allergan, Inc.
Tech Street: 2525 Dupont Drive,
Tech City: Irvine
Tech State/Province: CA
Tech Postal Code: 92612
Tech Country: US
Tech Phone: +1.7142466799
Tech Phone Ext:
Tech Fax: +1.7142462418
Tech Fax Ext:
Tech Email: Email Masking Image@allergan.com
Name Server: ns5.markmonitor.com
Name Server: ns2.markmonitor.com
Name Server: ns4.markmonitor.com
Name Server: ns1.markmonitor.com
Name Server: ns3.markmonitor.com
Name Server: ns6.markmonitor.com
Name Server: ns7.markmonitor.com
Think that means anything? I'm long DNDN and don't think Allergan is the buyer. I can't even access that website domain so it must be inactive. Maybe at one time Allergan was thinking about or talks to acquire. I think Novartis is more likely candidate with the need for their immuno brain cancer delivery system.
You have to admit it is very compelling. Revenues have to sky rocket. Imagine if results show no advantage to CHEMO and the FDA makes it a first line treatment too? Crazy stuff. Just the possibility can make this stock run emotionally.
Novartis AG (NOVN) has a promising therapy for cancer. It’s just not sure how to get it to patients easily.
The treatment is so potent that it cleared malignant cells in about 90 percent of patients facing almost certain death from the most common form of cancer in children.
The approach involves taking T cells, part of the body’s immune system, from the blood and engineering them to identify proteins on cancer cells. When returned to the patient’s bloodstream, the revamped T cells seek and destroy cancer cells. It’s so specific that a single mistake can mean death for a patient, and so turbo-charged that Novartis plans to set up a network of hospitals versed in treating the spiking fever, chills and flu-like symptoms that may come as side effects.
“The question is really if this is the right way to go at immunotherapy,” a burgeoning field of medicine that empowers the immune system to fight diseases such as cancer, Michael Leuchten, an analyst at Barclays Plc in London, said in an interview.
Cancer cells can use proteins on their surfaces as biological cloaks of invisibility to elude detection by the immune-system cells policing the body. Immunotherapies include checkpoint agents, drugs that strip away such disguises and expose cancer cells to attack; products such as Dendreon Corp. (DNDN)’s Provenge, which combines a patient’s immune cells with vaccine components in an infusion; and so-called biconjugated antibodies that help immune cells anchor themselves to cancerous ones.